Shire and Kamada announced that the FDA has approved an expanded label for Glassia (alpha antitrypsin IV), marking the first...
Baxalta, spun out of Baxter, launches on 1 July 2015 to develop and promote products in haematology, immunology and to...
Thrombolytic microangiopathy and graft versus host disease are potentially life-threatening complications of haematopoietic stem cell transplantation.